|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of nonalcoholic fatty liver disease显示文摘不含酒精的脂肝疾病(NAFLD ) 是为在发达国家的提高的肝酶的最普通的原因。在因为超重孩子的增加的数字,具有特别兴趣的预防节目以外,处理应该集中于最重要的风险因素,肥胖和抗胰岛素性。作为阐明的后果 NAFLD 的 pathomechanisms,潜在的治疗学的选择的数字增加了。然而,调查治疗学的效果的许多研究在至少一个下列点显示出缺点:连续的肝活体检视,治疗的短术语和包括的病人的有限数字的缺乏。第二产生胰岛素抗体 pioglitazone 和 rosiglitazone 为注意在 NAFLD,而是重量获得和潜在的 hepatotoxicity 电话显示出最有希望的改进。在结论,为特定的药的应用程序的一个一般建议不能被给。在肥胖的病人改进胰岛素敏感度的而且控制的临床的试用,体重减轻和物理活动应该是优先级目的。 | Juergen Siebler Peter R Galle | 2006 | World Journal of Gastroenterology2006，12，14： | 16 |
| 2 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 3 | Advances in hepatitis C therapy: What is the current state-what come's next?显示文摘Chronic hepatitis C virus(HCV) infection affects 80-160 million people worldwide and is one of the leading causes of chronic liver disease.It is only a few years ago that standard treatment regimes were based on pegylated interferon alpha and ribavirin.However,treatment of HCV has undergone a revolutionary change in recent years.The admission of the nucleotide polymerase inhibitor Sofosbuvir enabled an interferon-free regimen with direct antiviral agents(DAA).Meanwhile seven DAAs are available and can be applied in several combinations for 8 to 24 wk depending on HCV genotype and patient characteristics such as cirrhosis and chronic renal failure.High rates of sustained virological response(SVR) rates can be achieved with these novel drugs.Even in difficult to treat populations such as patients with liver cirrhosis,HCV-human immunodeficiency virus co-infections,after liver transplantion,or with chronic kidney disease comparable high rates of SVR can be achieved.The anticipated 2nd generation DAAs are strikingly effective in patients so far classified as difficult to treat including decompensated liver cirrhosis or posttransplant patients.These 2nd generations DAAs will have higher resistance barriers,higher antiviral effects and a pan-genotypic spectrum.This review highlights the current state of the art of antiviral treatment in hepatitis Cand gives an outlook for upcoming therapies. | Steffen Zopf Andreas E Kremer Markus F Neurath Juergen Siebler | 2016 | World Journal of Hepatology2016，8，3： | 7 |
| 4 | Expression of Tissue Factor in High-Grade Carotid Artery Stenosis: Association With Plaque Destabilization显示文摘 | Sebastian Jander Matthias Sitzer Angélique Wendt Michael Schroeter Martin Buchkremer Mario Siebler Wolfram Müller Wilhelm Sandmann Guido Stoll | 2001 | Stroke: Journal of the American Heart Association2001，，4： | 3 |
| 5 | Comparison of Hemospray~? and Endoclot? for the treatment of gastrointestinal bleeding显示文摘BACKGROUND Gastrointestinal(GI) bleeding is a common indication for endoscopy. For refractory cases, hemostatic powders(HP) represent 'touch-free' agents.AIM To analyze short term(ST-within 72 h-) and long-term(LT-within 30 d-) success for achieving hemostasis with HP and to directly compare the two agents Hemospray(HS) and Endoclot(EC).METHODS HP was applied in 154 consecutive patients(mean age 67 years) with GI bleeding.Patients were followed up for 1 mo(mean follow-up: 3.2 mo).RESULTS Majority of applications were in upper GI tract(89%) with following bleeding sources: peptic ulcer disease(35%), esophageal varices(7%), tumor bleeding(11.7%), reflux esophagitis(8.7%), diffuse bleeding and erosions(15.3%). Overall ST success was achieved in 125 patients(81%) and LT success in 81 patients(67%). Re-bleeding occurred in 27% of all patients. In 72 patients(47%), HP was applied as a salvage hemostatic therapy, here ST and LT success were 81% and64%, with re-bleeding in 32%. As a primary hemostatic therapy, ST and LT success were 82% and 69%, with re-bleeding occurring in 22%. HS was more frequently applied for upper GI bleeding(P = 0.04)CONCLUSION Both HP allow for effective hemostasis with no differences in ST, LT success and re-bleeding. | Francesco Vitali Andreas Naegel Raja Atreya Steffen Zopf Clemens Neufert Juergen Siebler Markus F Neurath Timo Rath | 2019 | World Journal of Gastroenterology2019，25，13： | 2 |
| 6 | Safety and efficacy of CPT-11/CF/5-Fu(IFL) versus FLF in previously untreaeed advanced or metastatic adoenocarcinoma of the stomach or gastroesophageal junction显示文摘 | Moehler MH Siebler J Hoehler T | 2003 | Proc AmSoc Clin Oncol2003，22，5： | 1 |
| 7 | Thyroid hormones regulate hypertrophic chondro-cyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation显示文摘 | Stevens DA Hasserjian RP Robson H Siebler T Shalet SM Williams GR | | 0，，： | 1 |
| 8 | Cerebral microembolism is blocked by tirofiban,a selective nonpeptide platelet glycoprotein Ⅱb/Ⅲ a receptor antagonist显示文摘 | Junghans U Siebler M | 2003 | Circulation2003，107，21： | 1 |
| 9 | Glucocorticoids, thyroid hormone and growth hormone interactions: implications for the growth plate显示文摘 | Siebler T Robson H Shalet SM | 2001 | Horm Res2001，56，1： | 1 |
| 10 | Interactions between GH,IGF-I,glucoeorticoids,and thyroid hormones during skeletal growth显示文摘 | Robson H Siebler T Shalet SM | 2002 | Pediatr Res2002，52，： | 1 |
| 11 | Immunologically induced electrophysiological dysfunction:implications for inflammatory diseases显示文摘 | Siebler M Hartung HP | 1997 | Prog Neurobiol1997，52，1： | 1 |
| 12 | Virtual arterial endoscopy as a diagnostic aid in a patient with basilar artery fenestration and thromboembolic pontine infarct显示文摘 | Scherer A Siebler M Aulich A | | 0，，： | 1 |
| 13 | Cerebral microembolism is blocked by tirofiban,a selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa receptor antagonist显示文摘 | Junghans U Siebler M | 2003 | Circulation2003，107，21： | 1 |
| 14 | Virtual arterial endoscopy as a diagnostic aid in a patient with basilar artery fenestration and thromboembolic pontine infarct显示文摘 | Scherer A Siebler M Aulich A | 2002 | AJNR2002，23，7： | 1 |
| 15 | Cutting edge: a key pathogenic role of IL-27 in T cell- mediated hepatitis显示文摘 | Siebler J Wirtz S Frenzel C | 2008 | Immunol2008，180，1： | 1 |
| 16 | Thyroid hormone acts di- rectly on growth platech and rocytes to promote hypertrophic differ- entiation and inhibit clonal expansion and cell proliferation 显示文摘 | Robson H Siebler T Stevens DA | 2000 | En- docrinology2000，141，10： | 1 |
| 17 | Leptin serum concentrations in healthy neonates within the first week of life: relation to insulin and growth hormone levels, skinfold thickness, body mass index and weight显示文摘 | Siebler T Kratzsch J | 1999 | Clin Endocrinol(Oxf)1999，51，2： | 1 |
| 18 | Expression of Tissue Factor in High-Grade Carotid Artery Stenosis: Association With Plaque Destabilization显示文摘 | Sebastian Jander Matthias Sitzer Angélique Wendt Michael Schroeter Martin Buchkremer Mario Siebler Wolfram Müller Wilhelm Sandmann Guido Stoll | 2001 | Stroke: Journal of the American Heart Association2001，，4： | 1 |
| 19 | Virtual arterial endoscopy as a di agnostic aid in a patient with hasilar artery fenestration and thromboembolic infarct显示文摘 | Seherer A Siebler M Aulich A | 2002 | AJNR2002，23，7： | 1 |
| 20 | Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth显示文摘 | Robson H Siebler T Shalet SM | 2002 | Pediatr Res2002，52，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员